Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Johnson and Johnson
Accenture
Fish and Richardson
Cerilliant
Federal Trade Commission
Dow
Express Scripts
Baxter
Novartis

Generated: February 19, 2018

DrugPatentWatch Database Preview

Otsuka America Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for OTSUKA AMERICA PHARM, and when can generic versions of OTSUKA AMERICA PHARM drugs launch?

OTSUKA AMERICA PHARM has one approved drug.

There are two US patents protecting OTSUKA AMERICA PHARM drugs.

There are sixty-four patent family members on OTSUKA AMERICA PHARM drugs in nineteen countries and five supplementary protection certificates in four countries.

Summary for Otsuka America Pharm
International Patents:64
US Patents:2
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Otsuka America Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Otsuka America Pharm SAMSCA tolvaptan TABLET;ORAL 022275-002 May 19, 2009 RX Yes Yes 5,753,677 ➤ Sign Up ➤ Sign Up
Otsuka America Pharm SAMSCA tolvaptan TABLET;ORAL 022275-001 May 19, 2009 RX Yes No 5,753,677 ➤ Sign Up ➤ Sign Up
Otsuka America Pharm SAMSCA tolvaptan TABLET;ORAL 022275-002 May 19, 2009 RX Yes Yes 8,501,730 ➤ Sign Up Y ➤ Sign Up
Otsuka America Pharm SAMSCA tolvaptan TABLET;ORAL 022275-003 May 19, 2009 DISCN Yes No 5,753,677 ➤ Sign Up ➤ Sign Up
Otsuka America Pharm SAMSCA tolvaptan TABLET;ORAL 022275-003 May 19, 2009 DISCN Yes No 8,501,730 ➤ Sign Up Y ➤ Sign Up
Otsuka America Pharm SAMSCA tolvaptan TABLET;ORAL 022275-001 May 19, 2009 RX Yes No 8,501,730 ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Otsuka America Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Otsuka America Pharm SAMSCA tolvaptan TABLET;ORAL 022275-001 May 19, 2009 5,258,510 ➤ Sign Up
Otsuka America Pharm SAMSCA tolvaptan TABLET;ORAL 022275-003 May 19, 2009 5,258,510 ➤ Sign Up
Otsuka America Pharm SAMSCA tolvaptan TABLET;ORAL 022275-002 May 19, 2009 5,258,510 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for OTSUKA AMERICA PHARM drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 15 mg and 30 mg ➤ Subscribe 9/23/2013

Non-Orange Book US Patents for Otsuka America Pharm

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,258,510 United States Patent: 5258510   ( 1 ➤ Sign Up
8,273,735 Process for preparing benzazepine compounds or salts thereof ➤ Sign Up
5,559,230 Benzoheterocyclic compounds ➤ Sign Up
5,985,869 Benzoheterocyclic compounds ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Otsuka America Pharm Drugs

Supplementary Protection Certificates for Otsuka America Pharm Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0408 Netherlands ➤ Sign Up 300408, 20101018, EXPIRES: 20151017
2009 00031 Denmark ➤ Sign Up
C0049 France ➤ Sign Up PRODUCT NAME: TOLVAPTAN, EVENTUELLEMENT SOUS FORME DE SEL; REGISTRATION NO/DATE: EU/1/09/539/001 20090803
00408 Netherlands ➤ Sign Up PRODUCT NAME: TOLVAPTAN, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/09/539/001-004 20090803
C/GB09/037 United Kingdom ➤ Sign Up PRODUCT NAME: TOLVAPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/09/539/001 20090803; UK EU/1/09/539/002 20090803; UK EU/1/09/539/003 20090803; UK EU/1/09/539/004 20090803
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
US Department of Justice
QuintilesIMS
Chinese Patent Office
Harvard Business School
Merck
Moodys
McKinsey
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot